



**Adelene Q. Perkins** has served as [Infinity's](#) president and chief executive officer since 2009. Ms. Perkins first joined Infinity as chief business officer in 2002 and then served as president and chief business officer of Infinity from 2008-2009. Since joining Infinity, she has played an integral role in developing Infinity's business strategy, leading the company in its transition from a platform- to a product-based organization. She has also been the principal figure in structuring, executing, and managing all of Infinity's innovative strategic relationships, including its global alliance with Mundipharma International Corporation Ltd. and Purdue Pharmaceutical Products L.P.

Ms. Perkins has more than 25 years of international business and corporate strategy experience in the biopharmaceutical industry, focused on licensing and business development, strategic finance, product life cycle management, and leading high-caliber, cross-functional teams.

Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and as an early member of the management team that built the company prior to its acquisition by J&J. From 1992-1999, she was vice president of emerging businesses and the co-founder and general manager of the DiscoverEaseT business unit at Genetics Institute, now part of Pfizer. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.

Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Board of Project Hope and the Villanova University College of Engineering Advisory Board.